In the evolving landscape of international tax policy, the discourse on the United States’ approach as influenced by the Tax Cuts and Jobs Act (TCJA) of 2017 is ongoing. Recent analysis, particularly from policy professionals, argues for a competitive tax environment that reinforces US corporate investment domestically while maintaining national security priorities.
The TCJA was marked by a significant shift from a 35% corporate tax rate to a more globally competitive rate, alongside new international provisions designed to curb profit shifting and incentivize domestic economic activity. These changes have reportedly underpinned a surge in investment and innovation, particularly within the biopharmaceutical sector. According to the Alliance for Biopharmaceutical Competitiveness and Innovation, since the TCJA’s enactment, research and development spending by major US biopharmaceutical companies reached unprecedented levels, with $624.2 billion invested in R&D and a 55% increase in US manufacturing sites.
This legislative reform halted the trend of corporate inversions, where US companies relocated headquarters overseas for tax advantages. From 2004 to 2014, 47 US companies had engaged in such inversions. Post-2017, however, the allure of relocating diminished, resulting in a more stable corporate presence within US borders. This is further substantiated by the data on acquisitions, highlighting that over 80% of sizeable transactions were made by US entities between 2021 and 2024.
The broader implications of maintaining a competitive tax system also align with national security considerations. The National Security Commission on Emerging Biotechnology has identified the need for the US to reduce its reliance on foreign, particularly Chinese, supply chains in critical sectors like biotechnology. Ensuring robust domestic capabilities in pharmaceuticals and related fields enhances both economic and strategic resilience.
Recommendations from the industry call for sustaining the competitive tax framework, particularly as certain TCJA provisions are due for reconsideration. Preserving incentives such as the Global Intangible Low-Taxed Income (GILTI) and foreign-derived intangible income rules could be pivotal in keeping the US an attractive destination for business innovation.
The debate continues on how best to balance tax policy to ensure expansive R&D investment while keeping the US at the forefront of economic and technological leadership on the global stage. To explore further perspectives on this issue, refer to Greg Nickerson’s detailed analysis.